Evidence map›Paper›PMID 25015641›Full record

ReviewStem cells translational medicine2014

Concise review: injectable biomaterials for the treatment of myocardial infarction and peripheral artery disease: translational challenges and progress.

Jessica L Ungerleider, Karen L Christman

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cells translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 111 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Targeted delivery of engineered adipose-derived stem cell secretome to promote cardiac repair after myocardial infarction.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Hydrogel Formation with Enzyme-Responsive Cyclic Peptides.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  17. 2D Materials for Cardiac Tissue Repair and Regeneration.Frontiers in cardiovascular medicine · 2022
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jessica L UngerleiderDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, California, USA.
Karen L ChristmanDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, California, USA christman@eng.ucsd.edu.
Sanford Consortium for Regenerative Medicine · USUniversity of California, San Diego · US

Funding

Extracellular matrix hydrogels for treating ischemiaR01HL113468 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHRISTMAN, KAREN L · 2012 to 2020
$3.1M
NHLBI NIH HHS 5R01HL113468NHLBI NIH HHS R01 HL113468
6 · The paper itself

Abstract

Recently, injectable biomaterial-based therapies for cardiovascular disease have been gaining attention, because they have shown therapeutic potential in preclinical models for myocardial infarction (MI) and peripheral artery disease (PAD). Naturally derived (e.g., alginate, hyaluronic acid, collagen, or extracellular matrix-based) or synthetic (e.g., peptide or polymer-based) materials can enhance stem cell survival and retention in vivo, prolong growth factor release from bulk hydrogel or particle constructs, and even stimulate endogenous tissue regeneration as a standalone therapy. Although there are many promising preclinical examples, the therapeutic potential of biomaterial-based products for cardiovascular disease has yet to be proved on a clinical and commercial scale. This review aims to briefly summarize the latest preclinical and clinical studies on injectable biomaterial therapies for MI and PAD. Furthermore, our overall goal is to highlight the major challenges facing translation of these therapies to the clinic (e.g., regulatory, manufacturing, and delivery), with the purpose of increasing awareness of the barriers for translating novel biomaterial therapies for MI and PAD and facilitating more rapid translation of new biomaterial technologies.

Indexed as

AnimalsBiocompatible MaterialsCell- and Tissue-Based TherapyDrug Delivery SystemsHumansHydrogel, Polyethylene Glycol DimethacrylateMyocardial InfarctionPeripheral Arterial DiseaseBiocompatible MaterialsHydrogel, Polyethylene Glycol DimethacrylateBiocompatible materialsMyocardial infarctionPeripheral arterial diseaseTranslational medical research

Identifiers

PMID25015641
PMCPMC4149304
OpenAlexW2152222294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.